Jacobio Pharma Partners with Oceanpine Capital for Oncology Pipeline Advancement

Strategic Partnership for Oncology Development

Jacobio Pharma has officially announced a significant partnership with Oceanpine Capital, marking a pivotal step in its commitment to advancing cancer treatments. The agreement involves a capital increase and equity transfer strategy that centers on enhancing Jacobio’s core oncology pipeline, particularly through its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd.

On October 15, 2025, Jacobio revealed that Oceanpine Capital would acquire an impressive 80% equity stake in Beijing Jacobio's project company, Jacoray, for a total sum of RMB 200 million. This amount consists of an upfront payment of RMB 125 million, along with a subsequent milestone payment of RMB 75 million. Following the transaction, ownership will be distributed with Beijing Jacobio retaining 10% equity, Oceanpine Capital holding 80%, and an industry partner possessing another 10%.

Focused on Cardiovascular and Oncology Innovations

Jacoray's main thrust is its early-stage cardiovascular research project, but this partnership is particularly significant for Jacobio's overarching strategy aimed at oncology innovation. The funding derived from this partnership is expected to primarily fuel research and development efforts, production, and marketing endeavors related to Jacobio’s pioneering Pan-KRAS inhibitor and other oncology assets.

As part of this arrangement, Dave Chenn, the founder and CEO of Oceanpine Capital, expressed strong confidence in Jacobio's scientific acumen, emphasizing the firm’s commitment to fostering advancements in the global biotech sphere. Chenn noted, “Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalization of China’s biotech innovation.”

Meanwhile, Dr. Yinxiang Wang, chairman of Jacobio, remarked that this collaboration with Oceanpine Capital not only underlines their strategic focus on oncology innovation but also reinforces their long-term commitment to developing next-generation cancer therapies.

Jacobio’s Commitment to Breakthrough Treatments

Jacobio Pharma is firmly dedicated to delivering groundbreaking treatments for patients grappling with serious ailments. Its induced allosteric drug discovery platform places particular emphasis on the KRAS pathway, a critical area in cancer research. The company is actively working to establish itself as a global leader in research and development, while simultaneously seeking strategic partnerships to drive forward-thinking innovations. Jacobio has research and development centers strategically located in Beijing, Shanghai, and Boston, alongside clinical trials being conducted across more than 200 sites worldwide, including over 180 sites in China and several in the USA and Europe.

This partnership with Oceanpine Capital is a crucial step in Jacobio’s long-term vision of transforming healthcare through innovative oncology solutions. With such promising potential on the horizon, Jacobio aims to harness the power of this collaboration to bring about remarkable advancements in cancer treatment, reinforcing its pivotal role in the global biotech landscape.

For more detailed insights and updates about Jacobio's ongoing projects, visit their official website here.